<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03642834</url>
  </required_header>
  <id_info>
    <org_study_id>ICP-CL-00201</org_study_id>
    <nct_id>NCT03642834</nct_id>
  </id_info>
  <brief_title>Study of ICP-105 in Solid Tumors Patients</brief_title>
  <official_title>A Phase I, Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics of ICP-105 in Patients With Advanced Solid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing InnoCare Pharma Tech Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing InnoCare Pharma Tech Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open-label, non-randomized, Phase I, dose-escalating, first-in-man study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consisted of a screening period, a treatment period with repeated 28-day treatment&#xD;
      cycles (duration treatment with ICP-105), and a follow-up period (within 30 days of the last&#xD;
      dose and post-treatment follow-up 30 days after the last visit). The recruited patients&#xD;
      receive a single dose on day 1, then after a 3-day washout period, multiple dosing will be&#xD;
      initiated following dose-escalation schedule. The dose-limiting toxicity (DLT) assessment&#xD;
      period consisted of Cycle 0 (single dose and washout period) and Cycle 1 (28-day cycle).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 31, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>Every cycle (28 days) for approximately 24 months or earlier if patient terminates from the study</time_frame>
    <description>will be evaluated by CTCAE v4.03</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>Every cycle (28 days) for approximately 24 months or earlier if patient terminates from the study</time_frame>
    <description>the peak plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
    <time_frame>Every cycle (28 days) for approximately 24 months or earlier if patient terminates from the study</time_frame>
    <description>area under the plasma concentration vs. time curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent half-life for designated elimination phases (t½)</measure>
    <time_frame>Every cycle (28 days) for approximately 24 months or earlier if patient terminates from the study</time_frame>
    <description>will be measured and calculated with noncompartmental analysis using WinNonlin</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>ICP-105 Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ICP-105 of multiple dose levels, dose escalation steps may be modified based on the safety from the previous dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ICP-105</intervention_name>
    <description>25mg, 100mg capsule</description>
    <arm_group_label>ICP-105 Single Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 Years and older.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1.&#xD;
&#xD;
          -  At least one evaluable disease according to RECIST1.1.&#xD;
&#xD;
          -  Histologically or cytologically confirmed solid tumors, failure to respond to standard&#xD;
             therapy, or for whom standard therapy does not exist.&#xD;
&#xD;
          -  Adequate bone marrow, liver, renal, and cardiovascular function.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous treatment with FGF19, FGFR4 inhibitors and/or pan-FGFR inhibitors.&#xD;
&#xD;
          -  Anti-cancer therapy, such as chemotherapy, immunotherapy, hormonal, targeted therapy,&#xD;
             or investigational agents within four weeks of the first dose of ICP-105.&#xD;
&#xD;
          -  Major surgery within 6 weeks of the first dose of ICP-105.&#xD;
&#xD;
          -  Significant GI disorder(s) that could interfere with the absorption, metabolism, or&#xD;
             excretion of ICP-105.&#xD;
&#xD;
          -  Crohn's disease with symptoms and systemic treatment.&#xD;
&#xD;
          -  Central nervous system (CNS) metastasis.&#xD;
&#xD;
          -  Current clinically significant cardiovascular disease including:&#xD;
&#xD;
          -  Any class 3 or 4 cardiac disease such as arrhythmia, congestive heart failure or&#xD;
             myocardial infarction defined by the New York Heart Association Functional&#xD;
             Classification, or left ventricular ejection fraction (LVEF) &lt; 50%, Primary&#xD;
             cardiomyopathy, clinical significant QTc prolong history or QTc&gt;470ms (female)&#xD;
             QTc&gt;450ms (male).&#xD;
&#xD;
          -  Known active bleeding within 2 months of screening or 6 months of bleeding history.&#xD;
&#xD;
          -  Lung function impairment by pleural effusion or ascites, any history of interstitial&#xD;
             pneumonia, deep vein thrombosis, pulmonary embolism.&#xD;
&#xD;
          -  Known active infection with HBV, HCV or HIV or any uncontrolled active systemic&#xD;
             infection.&#xD;
&#xD;
          -  Non-hematological toxicity must recover to ≤ Grade 1 from prior anti-cancer therapy&#xD;
             (excluding alopecia, nausea and vomiting).&#xD;
&#xD;
          -  Lactating or pregnant women, or women who will not use contraception during the study&#xD;
             and for 180 days after the last dose of study drug if sexually active and able to bear&#xD;
             children.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin Li, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai East Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jin Li, PhD</last_name>
    <phone>8621-38804518</phone>
    <phone_ext>22132</phone_ext>
    <email>lijin@csco.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Siwei Bao, PhD</last_name>
    <phone>8621-38804518</phone>
    <phone_ext>22198</phone_ext>
    <email>siwei_bao@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai East Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin Li, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 17, 2018</study_first_submitted>
  <study_first_submitted_qc>August 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 22, 2018</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

